GSA Capital Partners LLP bought a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 43,274 shares of the biopharmaceutical company's stock, valued at approximately $1,567,000.
Several other institutional investors also recently made changes to their positions in the stock. GAMMA Investing LLC boosted its position in shares of Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 323 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at about $35,000. ANTIPODES PARTNERS Ltd acquired a new position in Ultragenyx Pharmaceutical in the 1st quarter valued at about $57,000. GF Fund Management CO. LTD. acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at about $82,000. Finally, Quarry LP acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at about $84,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Ultragenyx Pharmaceutical
In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the transaction, the director directly owned 15,344 shares in the company, valued at $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.50% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on RARE. William Blair began coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They issued an "outperform" rating and a $65.00 target price for the company. Morgan Stanley cut their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. HC Wainwright raised shares of Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 price objective for the company in a research note on Monday, July 28th. Wells Fargo & Company dropped their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research note on Thursday, July 10th. Finally, Wedbush dropped their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research note on Monday, July 14th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $82.57.
Read Our Latest Stock Report on Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Price Performance
RARE traded up $1.12 during trading on Friday, hitting $28.44. The company had a trading volume of 2,239,592 shares, compared to its average volume of 3,190,304. The company has a market cap of $2.69 billion, a PE ratio of -4.84 and a beta of 0.25. The business has a 50-day moving average of $33.99 and a 200-day moving average of $37.21. Ultragenyx Pharmaceutical Inc. has a 1-year low of $25.81 and a 1-year high of $60.37.
Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.03). The company had revenue of $139.29 million during the quarter, compared to analyst estimates of $145.98 million. Ultragenyx Pharmaceutical had a negative net margin of 93.04% and a negative return on equity of 186.49%. The company's revenue was up 28.0% on a year-over-year basis. During the same period in the prior year, the company earned ($2.03) earnings per share. Research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.
Ultragenyx Pharmaceutical Company Profile
(
Free Report)
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Featured Articles

Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.
While Ultragenyx Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.